Takuya Nagashima
Overview
Explore the profile of Takuya Nagashima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
293
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Isaka T, Nagashima T, Washimi K, Saito H, Narimatsu H, Shigefuku S, et al.
J Cachexia Sarcopenia Muscle
. 2025 Mar;
16(2):e13751.
PMID: 40035113
Background: The impact of lobectomy versus segmentectomy on body composition changes, particularly adipose tissue, in patients with early-stage lung cancer remains unclear. This study aimed to determine the association between...
2.
Kamigaichi A, Mimae T, Tsubokawa N, Miyata Y, Kudo Y, Nagashima T, et al.
Interdiscip Cardiovasc Thorac Surg
. 2025 Feb;
40(2).
PMID: 39928361
Objectives: Despite clinical trials supporting the efficacy of segmentectomy for early-stage non-small cell lung cancer (NSCLC), a previous report indicated its limited efficacy in younger patients, raising concerns about its...
3.
Otabe M, Mimae T, Miyata Y, Tsubokawa N, Kudo Y, Nagashima T, et al.
Jpn J Clin Oncol
. 2025 Feb;
PMID: 39909863
Background: This study aimed to elucidate the significance of the maximum standardized uptake value (SUVmax) on 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) by radiological ground glass opacity (GGO) tumors of non-small...
4.
Akimoto H, Nagashima T, Minagawa K, Hayakawa T, Takahashi Y, Asai S
Pharmacol Res Perspect
. 2025 Feb;
13(1):e70055.
PMID: 39908147
The dose-response relationship between metformin and change in hemoglobin A1c (HbA1c) shows a maximum at 1500-2000 mg/day in patients with type 2 diabetes (T2D) in the U.S. In Japan, there...
5.
Takahashi Y, Minagawa K, Nagashima T, Hayakawa T, Akimoto H, Asai S
Clin Transl Sci
. 2024 Dec;
17(12):e70088.
PMID: 39692694
SGLT2 inhibitors show promise in reducing hospitalization for heart failure in diabetics, but their long-term effects and time-dependency remain unclear. We conducted a retrospective nested case-control study within a large...
6.
Adachi H, Ito H, Nagashima T, Isaka T, Murakami K, Shigefuku S, et al.
J Thorac Cardiovasc Surg
. 2024 Sep;
PMID: 39260599
Objective: Although recent trials on intentional segmentectomy have made mediastinal lymph node dissection (MLND) mandatory, the necessity of MLND in segmentectomy remains uncertain. We conducted a retrospective study to evaluate...
7.
Minagawa K, Hayakawa T, Akimoto H, Nagashima T, Takahashi Y, Asai S
Psychopharmacology (Berl)
. 2024 Aug;
242(1):215-231.
PMID: 39177810
Rationale: Despite variants in the Dlgap1 gene having the two lowest p-value in a genome-wide association study of obsessive compulsive disorder (OCD), previous studies reported the absence of OCD-like phenotypes...
8.
Tsubokawa N, Mimae T, Saeki A, Miyata Y, Kanno C, Kudo Y, et al.
J Thorac Cardiovasc Surg
. 2024 Jul;
169(2):427-435.e2.
PMID: 38969057
Objectives: To determine the feasibility of segmentectomy in patients with central, whole tumor size ≤2 cm and radiologically solid-dominant cN0 non-small cell lung cancer (NSCLC). Methods: We retrospectively reviewed 1240...
9.
Murakami K, Ito H, Shigeta N, Kikunishi N, Shigefuku S, Isaka T, et al.
JTCVS Tech
. 2024 Jun;
25:177-179.
PMID: 38899085
No abstract available.
10.
Shigeta N, Murakami S, Yokose T, Isaka T, Shinada K, Nagashima T, et al.
Thorac Cancer
. 2024 May;
15(17):1343-1349.
PMID: 38698758
Background: Atezolizumab, one of the immune checkpoint inhibitors, has been approved as an adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II-IIIA non-small cell lung cancer with...